ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31

ARDELYX, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.09+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $766.53M
P/E (TTM): –
Dividend yield: –

ARDELYX, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	407	334	124	52	10	7.57	5.28	2.61	42	–	24	32	29	5.41
Cost of Revenue	40	51	18	4.12	1.00	0.15	0.60	0.47	8.40	–	–	–	–	–
Gross Profit	368	283	107	48	9.10	7.43	4.68	2.14	34	–	24	–	–	–
Research & Development	72	52	36	35	91	65	72	69	75	94	40	26	28	10
Selling, General & Admin	337	259	134	77	72	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	77	72	33	24	24	23	19	14	7.29	3.70	4.03
Operating Expenses	–	–	–	–	–	–	96	93	99	113	53	33	32	14
Total Costs & Expenses	448	362	188	112	163	98	97	94	–	–	–	–	–	–
Operating Income	-41	-28	-63	-64	-154	-91	-91	-91	-65	-113	-29	-1.56	-2.87	-8.81
Interest Expense	20	13	4.95	3.40	4.50	5.10	5.73	3.53	–	–	–	–	–	–
Other Non-Operating Income	8.75	9.17	6.63	1.63	0.69	1.57	2.35	3.19	1.96	0.51	-0.26	0.01	-0.05	-0.03
Merger & Restructuring Charges	–	–	–	–	6.20	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	0	0	0	0	0	0	0	0	–	–	–
Gain (Loss) on Sale of Assets	–	0	0	1.26	0	0	–	–	–	–	-0.07	–	–	–
Pretax Income	-61	-39	-66	-67	-158	-94	-95	-91	-63	-112	-30	-3.15	-6.42	-9.79
Income Tax Expense	0.97	0.27	0.55	0.01	0.00	0.00	0.30	0.00	1.18	–	-0.03	0.07	0.14	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	-94	-95	-91	-64	-112	-30	–	–	–
Net Income	-62	-39	-66	-67	-158	-94	-95	-91	-64	-112	-30	-3.21	-6.56	-9.79
EPS (Basic)(per share)	-0.26	-0.17	-0.30	-0.42	-1.52	-1.05	-1.47	-1.62	-1.36	-2.80	-1.29	-0.31	-5.82	-11.32
EPS (Diluted)(per share)	-0.26	-0.17	-0.30	-0.42	-1.52	-1.05	-1.47	-1.62	-1.36	-2.80	-1.29	-0.31	-5.82	-11.32
Shares Outstanding (Basic, Weighted)(shares)	241	235	219	159	104	90	64	56	47	40	23	10	1.13	0.86
Shares Outstanding (Diluted, Weighted)(shares)	241	235	219	159	104	90	64	56	47	40	23	10	1.13	0.86
EBITDA	-38	-26	-62	-63	-152	-88	-89	-88	-63	-112	-29	-1.26	-2.27	-8.13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 94.4%
Operating margin: -7.9%
Net margin: -12.4%
Return on equity, FY2025: -36.2%

Financial strength

Current ratio: 3.34
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 73.5%

Valuation

P/E ratio: –
Price to sales: 1.70
Price to book: 5.14
Dividend yield: –